IL150481A0 - 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors - Google Patents

2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Info

Publication number
IL150481A0
IL150481A0 IL15048101A IL15048101A IL150481A0 IL 150481 A0 IL150481 A0 IL 150481A0 IL 15048101 A IL15048101 A IL 15048101A IL 15048101 A IL15048101 A IL 15048101A IL 150481 A0 IL150481 A0 IL 150481A0
Authority
IL
Israel
Prior art keywords
group
mono
amino
nicotinamide derivatives
vegf
Prior art date
Application number
IL15048101A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL150481A0 publication Critical patent/IL150481A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
IL15048101A 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors IL150481A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001930.7A GB0001930D0 (en) 2000-01-27 2000-01-27 Organic compounds
PCT/EP2001/000835 WO2001055114A1 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IL150481A0 true IL150481A0 (en) 2002-12-01

Family

ID=9884488

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15048101A IL150481A0 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
IL150481A IL150481A (en) 2000-01-27 2002-06-27 Derivatives of 2-amino-nicotinamide and their use as inhibitors of tyrosine kinase VEGF receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150481A IL150481A (en) 2000-01-27 2002-06-27 Derivatives of 2-amino-nicotinamide and their use as inhibitors of tyrosine kinase VEGF receptor

Country Status (25)

Country Link
US (1) US6624174B2 (zh)
EP (2) EP1259487B8 (zh)
JP (1) JP3894793B2 (zh)
KR (1) KR100554988B1 (zh)
CN (1) CN1216867C (zh)
AT (1) ATE452880T1 (zh)
AU (1) AU771626B2 (zh)
BR (1) BR0107805A (zh)
CA (1) CA2396590C (zh)
CZ (1) CZ20022582A3 (zh)
DE (1) DE60140860D1 (zh)
ES (2) ES2338407T3 (zh)
GB (1) GB0001930D0 (zh)
HK (1) HK1050895A1 (zh)
HU (1) HUP0204083A3 (zh)
IL (2) IL150481A0 (zh)
MX (1) MXPA02007319A (zh)
NO (1) NO323826B1 (zh)
NZ (1) NZ520005A (zh)
PL (1) PL356307A1 (zh)
PT (2) PT2168948E (zh)
RU (1) RU2296124C2 (zh)
SK (1) SK287426B6 (zh)
WO (1) WO2001055114A1 (zh)
ZA (1) ZA200205988B (zh)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7419428B2 (en) * 2000-04-28 2008-09-02 Igt Cashless transaction clearinghouse
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
IL158783A0 (en) * 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
KR20050026535A (ko) * 2002-07-31 2005-03-15 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3 억제성 안트라닐아미도피리딘
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
EP1602647B1 (en) 2003-03-07 2013-10-16 Santen Pharmaceutical Co., Ltd. Novel compound having 4-pyridylalkylthio group as substituent
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
JP2007505939A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と他の治療剤の組み合わせ
WO2005027972A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
JP4724665B2 (ja) 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
NZ548949A (en) 2004-02-17 2009-09-25 Santen Pharmaceutical Co Ltd Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
EP1844136B1 (en) 2004-12-29 2014-08-27 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
WO2006093253A1 (ja) * 2005-03-03 2006-09-08 Santen Pharmaceutical Co., Ltd. キノリルアルキルチオ基を有する新規環式化合物
WO2006106914A1 (ja) 2005-03-31 2006-10-12 Santen Pharmaceutical Co., Ltd. ピリミジニルアルキルチオ基を有する新規環式化合物
KR101324863B1 (ko) 2005-05-17 2013-11-01 노파르티스 아게 헤테로고리 화합물의 합성 방법
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CA2627544C (en) 2005-11-29 2015-07-07 Novartis Ag Formulations of quinolinones for the treatment of cancer
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CA2676163A1 (en) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
JP5395058B2 (ja) 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
WO2009089271A1 (en) * 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Calibrator/control for simultaneous assay of proteins capable of complexing with one another
BRPI0909082A2 (pt) * 2008-03-26 2019-02-26 Novartis Ag imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
ES2445517T3 (es) 2008-08-27 2014-03-03 Leo Pharma A/S Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
BR112012005400A2 (pt) 2009-09-10 2016-04-05 Irm Llc derivados do tipo éter de heteroarilas bicíclicas
HUE043536T2 (hu) * 2009-10-06 2019-08-28 Millennium Pharm Inc PDK1 inhibitorként alkalmazható heterociklusos vegyületek
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
KR101412794B1 (ko) * 2011-07-27 2014-07-01 보령제약 주식회사 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
EP2846803B1 (en) * 2012-05-08 2017-06-21 Alpharmagen, LLC Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
ES2711882T3 (es) 2013-11-28 2019-05-08 B Creative Sweden Ab Método de tratamiento de la nefropatía diabética
CN114634483A (zh) 2014-02-21 2022-06-17 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝***酰胺
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
JP6882981B2 (ja) 2014-12-30 2021-06-02 セル キュア ニューロサイエンシズ リミテッド Ｒｐｅ細胞集団およびそれを作製する方法
US11230696B2 (en) 2015-07-29 2022-01-25 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
AU2016303632B2 (en) 2015-08-05 2022-09-29 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EA201890442A1 (ru) 2015-08-05 2018-07-31 Селл Кьюр Нейросайансес Лтд. Получение фоторецепторов для лечения заболеваний сетчатки
MX2018002574A (es) 2015-08-31 2019-02-25 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos.
EP3368661A1 (en) 2015-10-26 2018-09-05 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EP3595687A1 (en) 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
EP3730483B1 (en) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Class of pyrimidine derivative kinase inhibitors
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
EP3754014A1 (en) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automated method for preparing retinal pigment epithelium cells
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
EP4351334A1 (en) 2021-06-09 2024-04-17 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
KR20240038013A (ko) 2021-07-28 2024-03-22 리니지 셀 테라퓨틱스, 인크. 망막 색소 상피 세포의 확장
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058656T3 (es) 1989-04-20 1994-11-01 Boehringer Ingelheim Pharma 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida.
ATE384062T1 (de) * 1996-08-23 2008-02-15 Novartis Pharma Gmbh Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
EA003528B1 (ru) 1997-04-04 2003-06-26 Пфайзер Продактс Инк. Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d
AU8033598A (en) 1997-06-18 1999-01-04 Nissan Chemical Industries Ltd. Pyridine compounds and herbicides
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
AU4229999A (en) 1998-06-05 1999-12-20 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6610704B1 (en) 1998-12-23 2003-08-26 Eli Lilly And Company Antithrombotic amides
BR0009721A (pt) * 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
AU2001231143A1 (en) 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
GB0001930D0 (en) 2000-03-22
HK1050895A1 (en) 2003-07-11
RU2296124C2 (ru) 2007-03-27
ES2338407T3 (es) 2010-05-07
PT2168948E (pt) 2014-08-26
EP1259487A1 (en) 2002-11-27
PL356307A1 (en) 2004-06-28
NO20023218D0 (no) 2002-07-02
PT1259487E (pt) 2010-03-26
KR20020071973A (ko) 2002-09-13
US20030032656A1 (en) 2003-02-13
NO323826B1 (no) 2007-07-09
CN1396912A (zh) 2003-02-12
HUP0204083A3 (en) 2005-03-29
KR100554988B1 (ko) 2006-02-24
DE60140860D1 (de) 2010-02-04
SK287426B6 (sk) 2010-09-07
BR0107805A (pt) 2002-10-22
ES2490191T3 (es) 2014-09-03
NZ520005A (en) 2004-02-27
ATE452880T1 (de) 2010-01-15
IL150481A (en) 2009-09-22
JP2003520853A (ja) 2003-07-08
HUP0204083A2 (hu) 2003-03-28
WO2001055114A1 (en) 2001-08-02
MXPA02007319A (es) 2002-11-29
US6624174B2 (en) 2003-09-23
SK10852002A3 (sk) 2003-05-02
CN1216867C (zh) 2005-08-31
NO20023218L (no) 2002-09-16
EP2168948B1 (en) 2014-05-07
CZ20022582A3 (cs) 2002-10-16
EP2168948A1 (en) 2010-03-31
CA2396590A1 (en) 2001-08-02
CA2396590C (en) 2011-03-01
ZA200205988B (en) 2003-07-28
EP1259487B8 (en) 2014-04-23
EP1259487B1 (en) 2009-12-23
AU771626B2 (en) 2004-04-01
JP3894793B2 (ja) 2007-03-22
AU2849901A (en) 2001-08-07

Similar Documents

Publication Publication Date Title
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
IL128994A0 (en) Quinoline derivatives inhibiting the effect of growth factors such as vegf
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
TR200200749T2 (tr) Kinazolin bileşikleri ve bunları içeren farmasötik bileşikler.
ATE180468T1 (de) Anthranilsäure derivate
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
MX9804247A (es) Derivados de quinazolina.
DE69428476T2 (de) Heterocyclische Verbindungen als Bradykinin Antagonisten
EP1369418A4 (en) quinazoline derivatives
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
DK499385A (da) Piperazinforbindelser
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
NZ517315A (en) New derivatives of A-500359
WO2000075158A3 (en) NOVEL 6-PHENYLPURINE 9-β-D-RIBONUCLEOSIDES WITH ANTINEOPLASTIC ACTIVITY, THEIR USE FOR PREPARING PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS